The impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study
Clinical Infectious Diseases Jan 11, 2018
van Deursen AMM, et al. - Researchers here examined the direct effects of the 13-valent pneumococcal conjugate vaccine (PCV13) in community dwelling older adults as part of the randomized controlled Community Acquired Pneumonia immunization Trial in Adults (CAPiTA). In this work, a single dose of PCV13 seemed to elicit a small and temporary reduction in vaccine-type (VT)-carriage at 6 months post-vaccination in community-dwelling adults of 65 years and older. They recognized neither replacement by non-vaccine serotypes nor impact on other nasopharyngeal bacteria.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins